ATE555812T1 - Peg-interferon-beta-formulierungen - Google Patents

Peg-interferon-beta-formulierungen

Info

Publication number
ATE555812T1
ATE555812T1 AT08863833T AT08863833T ATE555812T1 AT E555812 T1 ATE555812 T1 AT E555812T1 AT 08863833 T AT08863833 T AT 08863833T AT 08863833 T AT08863833 T AT 08863833T AT E555812 T1 ATE555812 T1 AT E555812T1
Authority
AT
Austria
Prior art keywords
interferon beta
peg interferon
beta formulations
surfactant
buffer
Prior art date
Application number
AT08863833T
Other languages
English (en)
Inventor
Rio Alessandra Del
Joel Richard
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE555812T1 publication Critical patent/ATE555812T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT08863833T 2007-12-20 2008-12-18 Peg-interferon-beta-formulierungen ATE555812T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07150258 2007-12-20
US1025808P 2008-01-07 2008-01-07
PCT/EP2008/067876 WO2009080699A2 (en) 2007-12-20 2008-12-18 Peg-interferon-beta formulations

Publications (1)

Publication Number Publication Date
ATE555812T1 true ATE555812T1 (de) 2012-05-15

Family

ID=39760852

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08863833T ATE555812T1 (de) 2007-12-20 2008-12-18 Peg-interferon-beta-formulierungen

Country Status (20)

Country Link
US (1) US9138403B2 (de)
EP (1) EP2234645B1 (de)
JP (2) JP5563475B2 (de)
KR (1) KR20100099298A (de)
CN (1) CN101878043A (de)
AT (1) ATE555812T1 (de)
AU (1) AU2008340058A1 (de)
BR (1) BRPI0821029A2 (de)
CY (1) CY1112820T1 (de)
DK (1) DK2234645T3 (de)
EA (1) EA201070773A1 (de)
ES (1) ES2387236T3 (de)
HR (1) HRP20120483T1 (de)
IL (1) IL206441A0 (de)
PL (1) PL2234645T3 (de)
PT (1) PT2234645E (de)
RS (1) RS52417B (de)
SI (1) SI2234645T1 (de)
WO (1) WO2009080699A2 (de)
ZA (1) ZA201001908B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2234645T3 (pl) * 2007-12-20 2012-10-31 Merck Serono Sa Preparaty interferonu-beta modyfikowanego PEG
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta
JP6450364B2 (ja) * 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
WO2016052584A1 (ja) * 2014-09-30 2016-04-07 東レ株式会社 ポリエチレングリコール修飾インターフェロン－βの検出及び定量に使用する試料液の前処理方法、ポリエチレングリコール修飾インターフェロン－βの検出方法及び定量方法
PE20170922A1 (es) * 2014-11-10 2017-07-12 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones de accion prolongada de combinacion y procedimientos para hepatitis c
WO2016163764A2 (ko) * 2015-04-07 2016-10-13 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
CN116023466B (zh) * 2023-03-30 2023-06-27 北京生物制品研究所有限责任公司 纯化PEG修饰重组人干扰素β1b蛋白的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US4469228A (en) * 1983-05-31 1984-09-04 Schering Corporation Interferon kit
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
IT1244511B (it) 1991-04-15 1994-07-15 Isi Ist Sierovaccinogeno Ital Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione.
KR950014915B1 (ko) * 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
US5858001A (en) * 1995-12-11 1999-01-12 Elan Medical Technologies Limited Cartridge-based drug delivery device
ES2158611T3 (es) * 1996-12-20 2001-09-01 Alza Corp Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion.
IL130524A (en) 1996-12-24 2005-08-31 Biogen Idec Inc Stable liquid interferon formulations, a kit containing the same and a process for stabilizing the same
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
DE59811910D1 (de) * 1997-09-23 2004-10-07 Rentschler Biotech Gmbh Flüssige Interferon-Beta Formulierungen
CA2311681A1 (en) * 1997-12-08 1999-06-17 Genentech, Inc. Human interferon-epsilon: a type i interferon
BR9909087A (pt) 1998-03-26 2000-12-05 Schering Corp Formulações para proteção de conjugados peg-alfa interferon
AU762621B2 (en) 1998-04-28 2003-07-03 Merck Serono Sa Polyol-IFN-beta conjugates
HK1042434B (zh) * 1998-10-16 2008-01-25 生物基因Ma公司 干扰素-β-1A的聚合物缀合物及其使用
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
CA2379388C (en) 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
WO2002003472A2 (en) 2000-06-29 2002-01-10 California Institute Of Technology Aerosol silicon nanoparticles for use in semiconductor device fabrication
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
ATE373471T1 (de) 2000-12-27 2007-10-15 Ares Trading Sa Lipidmikropartikel mittels kryogenischer mikronisierung
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
EP1414498A2 (de) * 2001-06-29 2004-05-06 Maxygen Aps Stabilisierte formulierungen für interferon mit sulfoalkyl ether cyclodextrinen
EP1471891A4 (de) 2002-02-08 2007-04-11 Alkermes Inc Zusammensetzungen auf polymerbasis mit verzögerter freisetzung
CN1235939C (zh) * 2002-05-14 2006-01-11 北京键凯科技有限公司 靶向亲水性聚合物、及其与干扰素的结合物以及包含该结合物的药物组合物
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
AU2003256603C1 (en) * 2002-07-17 2010-07-15 Biogen Idec Ma Inc. Therapies for renal failure using interferon-Beta
WO2004050101A2 (en) 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
GEP20084486B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
CA2525399A1 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
AU2004266969B2 (en) * 2003-08-25 2010-02-25 Taniguchi, Tadatsugu Interferon-beta composite
RS52218B (sr) * 2003-12-11 2012-10-31 Ares Trading S.A. Stabilizovane tečne formulacije interferona
CA2556339A1 (en) * 2004-03-01 2005-09-15 David Ray Filpula Interferon-beta polymer conjugates
AU2005244448B2 (en) * 2004-05-17 2011-03-17 Ares Trading S.A. Hydrogel interferon formulations
ES2381674T3 (es) * 2004-06-01 2012-05-30 Ares Trading S.A. Método de estabilizar proteínas
US7731948B2 (en) * 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
MX2007001663A (es) * 2004-08-12 2007-04-10 Schering Corp Formulacion de interferon pegilado estable.
PL2234645T3 (pl) * 2007-12-20 2012-10-31 Merck Serono Sa Preparaty interferonu-beta modyfikowanego PEG

Also Published As

Publication number Publication date
CN101878043A (zh) 2010-11-03
PT2234645E (pt) 2012-05-21
WO2009080699A3 (en) 2009-11-26
EP2234645B1 (de) 2012-05-02
PL2234645T3 (pl) 2012-10-31
HRP20120483T1 (hr) 2012-07-31
WO2009080699A2 (en) 2009-07-02
US9138403B2 (en) 2015-09-22
US20100239529A1 (en) 2010-09-23
JP2014159445A (ja) 2014-09-04
AU2008340058A1 (en) 2009-07-02
RS52417B (sr) 2013-02-28
IL206441A0 (en) 2010-12-30
EA201070773A1 (ru) 2010-12-30
SI2234645T1 (sl) 2012-07-31
JP2011506562A (ja) 2011-03-03
DK2234645T3 (da) 2012-07-09
BRPI0821029A2 (pt) 2015-06-16
EP2234645A2 (de) 2010-10-06
JP5563475B2 (ja) 2014-07-30
ES2387236T3 (es) 2012-09-18
KR20100099298A (ko) 2010-09-10
CY1112820T1 (el) 2016-02-10
ZA201001908B (en) 2011-05-25

Similar Documents

Publication Publication Date Title
ATE555812T1 (de) Peg-interferon-beta-formulierungen
PL1817051T3 (pl) Kompozycje farmaceutyczne zawierające neurotoksynę botulinową, niejonowy środek powierzchniowo czynny, chlorek sodu oraz sacharozę
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
CL2011002941A1 (es) Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoico y acido monobenzoico de 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo; composicion farmaceutica; y uso en el tratamiento de asma, epoc, cancer, vih, hepatitis b y c, infecciones bacterianas.
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
DK1475101T3 (da) Antistof-holdige farmaceutiske opløsninger
PT2459167E (pt) Formulação subcutânea de anticorpo anti-her2
MEP18208A (en) Immune response modifier foam formulations
BR112013032396A2 (pt) formulações estáveis de aplicações relacionadas à enzima de degradação de ácido hialurônico
PE20090228A1 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
MX2010009850A (es) Analogos de insulina acilados y etabilizados contra proteasas.
DK1988913T3 (da) G-CSF-flydende formulering
BRPI0510654A (pt) formulações de interferon em hidrogel
DK2186830T3 (da) Polyethylenglycol modificeret interferon alpha 2B og fremstillingsfremgangsmåde og applikationer deraf
EP2215174A4 (de) Azeotropartige zusammensetzung von 1,1,1-trifluoro-3-chloropropen und methylformat
CL2007002634A1 (es) Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion.
TW200503754A (en) HSA-free stabilized interferon liquid formulations
NO20070187L (no) Oralt desintegrerende farmasoytisk preparat omfattende risperidon
IL204739A0 (en) Pharmaceutical compositions containing the enzyme cyprosin, an aspartic peptidase from cynara cardunculus and its inclusion in antitumour formulations
PE20171061A1 (es) Composiciones farmaceuticas de accion prolongada para hepatitis c
BRPI0716409A2 (pt) beta-interferona recombinante com atividade biolàgica aumentada
BRPI0504199B8 (pt) composições farmacêuticas baseadas em lopap e usos das ditas composições
GB0524375D0 (en) Novel liquid composition in vitro biologically active to viral infections
TH107361A (th) สารประกอบ 5,6-ไดไฮโดร-1h-ไพริดิน-2-โอน